BioNexus Gene Lab Corp.
BGLC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,544 | $2,260 | $2,137 | $2,524 |
| % Growth | 12.5% | 5.8% | -15.3% | – |
| Cost of Goods Sold | $2,166 | $1,892 | $1,794 | $2,215 |
| Gross Profit | $378 | $368 | $343 | $309 |
| % Margin | 14.8% | 16.3% | 16.1% | 12.3% |
| R&D Expenses | $15 | $13 | $12 | $48 |
| G&A Expenses | $446 | $517 | $392 | -$1,561 |
| SG&A Expenses | -$106 | $1,125 | -$149 | $469 |
| Sales & Mktg Exp. | -$552 | $608 | -$541 | $2,031 |
| Other Operating Expenses | $1,171 | -$158 | $1,099 | $209 |
| Operating Expenses | $1,080 | $979 | $962 | $725 |
| Operating Income | -$703 | -$611 | -$618 | -$416 |
| % Margin | -27.6% | -27% | -28.9% | -16.5% |
| Other Income/Exp. Net | -$6 | -$5 | -$5 | -$6 |
| Pre-Tax Income | -$709 | -$616 | -$623 | -$422 |
| Tax Expense | $0 | $0 | $0 | -$74 |
| Net Income | -$709 | -$616 | -$623 | -$348 |
| % Margin | -27.9% | -27.3% | -29.2% | -13.8% |
| EPS | -0.39 | -0.34 | -0.35 | -0.19 |
| % Growth | -14.7% | 2.9% | -84.2% | – |
| EPS Diluted | -0.39 | -0.34 | -0.35 | -0.19 |
| Weighted Avg Shares Out | 1,797 | 1,797 | 1,797 | 1,797 |
| Weighted Avg Shares Out Dil | 1,797 | 1,797 | 1,797 | 1,797 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21 | $30 | $24 | $148 |
| Interest Expense | $0 | $5 | $5 | $6 |
| Depreciation & Amortization | $43 | $42 | $40 | $43 |
| EBITDA | -$666 | -$570 | -$547 | -$373 |
| % Margin | -26.2% | -25.2% | -25.6% | -14.8% |